Breast最新文献

{"title":"Resource implications of evolving breast cancer radiotherapy treatment protocols","authors":"D.J. Coyle , B. McClean , R. Woods , F. Duane , J. Nicholson , O. McArdle","doi":"10.1016/j.breast.2024.103816","DOIUrl":"10.1016/j.breast.2024.103816","url":null,"abstract":"","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103816"},"PeriodicalIF":5.7,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of advanced oncoplastic surgery on breast-conserving surgery rates: A retrospective cohort study of 3,875 breast cancer procedures at a tertiary referral centre","authors":"Angus Reid ,&nbsp;Robert Thomas ,&nbsp;Andrew Pieri ,&nbsp;Adam Critchley ,&nbsp;Lorraine Kalra ,&nbsp;Jane Carter ,&nbsp;J.M. O'Donoghue ,&nbsp;Emily King ,&nbsp;Henry Cain","doi":"10.1016/j.breast.2024.103814","DOIUrl":"10.1016/j.breast.2024.103814","url":null,"abstract":"<div><h3>Introduction</h3><div>As the treatment of breast cancer advances, the focus has shifted from solely improving oncological endpoints to a greater weight being placed on cosmetic and psychological outcomes. The advent of advanced oncoplastic techniques allows for successful breast-conserving surgery (BCS) to patients who otherwise would have required a mastectomy. The aim of this study is to ascertain if the adoption of these procedures has assisted in the reduction of mastectomies performed.</div></div><div><h3>Methods</h3><div>A dataset of all breast cancer procedures based upon coding between April 2016 and July 2023 was evaluated, categorising procedures into: BCS, mastectomy, oncoplastic BCS and total reconstructions. R-Studio Software 4.3.1 (®) was used to explore statistical analysis and data visualisation. Registered as a clinical services evaluation study (Project ID: 14649).</div></div><div><h3>Results</h3><div>During the period stated, 3875 index breast cancer procedures were recorded (sample size = 3638 patients). The BCS rate increased from 66.2 % in 2016 to 80.7 % in 2023. Using a linear regression model, the BCS rate demonstrates an increase of 2.1 % each year (coefficient = 2.12, p-value = 0.0069). Concurrently, the rate of oncoplastic BCS increased from 10.5 % to 22.9 % (coefficient = 2.14, p-value = 0.00017). Using Pearson's product-moment, a positive correlation between these two variables is seen (coefficient = 0.86, p-value = 0.0056).</div></div><div><h3>Conclusion</h3><div>Having reviewed 3875 index breast cancer procedures over the past eight years, the BCS rate has shown a statistically significant increase and a positive correlation with the oncoplastic BCS rate. This suggests oncoplastic surgery has helped to reduce the rates of mastectomy at the centre.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103814"},"PeriodicalIF":5.7,"publicationDate":"2024-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142320241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Financial toxicity in breast cancer patients receiving regional nodal irradiation: Variation by cancer subtype","authors":"Grace L. Smith ,&nbsp;Benjamin D. Smith ,&nbsp;Chi-Fang Wu ,&nbsp;Simona F. Shaitelman ,&nbsp;Mariana Chavez-MacGregor ,&nbsp;Rashmi Murthy ,&nbsp;Kelsey Kaiser ,&nbsp;Kimberly S. Ku ,&nbsp;Julia J. Shi ,&nbsp;Sanjay S. Shete ,&nbsp;Ying-Shiuan Chen ,&nbsp;Robert J. Volk ,&nbsp;Sharon H. Giordano ,&nbsp;Ya-Chen T. Shih ,&nbsp;Karen E. Hoffman","doi":"10.1016/j.breast.2024.103813","DOIUrl":"10.1016/j.breast.2024.103813","url":null,"abstract":"<div><h3>Background</h3><div>We evaluated sociodemographic and clinical predictors of financial toxicity (FT) among patients with breast cancer with higher risk clinical factors warranting regional nodal irradiation (RNI).</div></div><div><h3>Methods</h3><div>Among 183 participants in a clinical trial of conventional vs. hypofractionated treatment with RNI, 125 (68 %) completed a pilot survey of FT measured using the validated Economic Strain and Resilience in Cancer (ENRICh) instrument, scored from 0 (minimal) to 10 (severe) FT. Associations with predictors were evaluated using Pearson correlation coefficients and Kruskal Wallis, Mann-Whitney U, and Jonckheere-Terpstra tests. Predictors of severe FT (ENRICh≥5) were tested using multivariable logistic regression with odds ratios converted to relative risks (RR).</div></div><div><h3>Results</h3><div>Of the sample, all received RNI, 92 % chemotherapy, 67 % axillary dissection, 26 % mastectomy without reconstruction, and 32 % mastectomy with reconstruction. At a median follow up of 1.48 years, median FT score was 2.13 (IQR 0.93–4.6), with 20.8 % of patients experiencing severe FT. Unadjusted worse FT score was associated with younger age (P = 0.003), Hispanic ethnicity (P = 0.006), lower income (P = 0.02), shorter interval from diagnosis to FT assessment (P = 0.02), and chemotherapy receipt (P = 0.05), but not with breast surgery type (P = 0.42), axillary surgery type (P = 0.33), or pathologic T (P = 0.68) or N stage (P = 0.47). In multivariable analysis, triple negative subtype was the sole clinical factor predicting severe FT (RR = 3.38; 95 % CI 1.48–4.99; P = 0.01).</div></div><div><h3>Conclusion</h3><div>Among patients with breast cancer receiving RNI, triple negative subtype was associated with severe FT, suggesting that tumor receptor subtype may help identify a key breast cancer subpopulation for early FT intervention.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103813"},"PeriodicalIF":5.7,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001449/pdfft?md5=240ce5758423ff46df0a8799495b11b8&pid=1-s2.0-S0960977624001449-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142315810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI-based strategies in breast mass ≤ 2 cm classification with mammography and tomosynthesis","authors":"Zhenzhen Shao ,&nbsp;Yuxin Cai ,&nbsp;Yujuan Hao ,&nbsp;Congyi Hu ,&nbsp;Ziling Yu ,&nbsp;Yue Shen ,&nbsp;Fei Gao ,&nbsp;Fandong Zhang ,&nbsp;Wenjuan Ma ,&nbsp;Qian Zhou ,&nbsp;Jingjing Chen ,&nbsp;Hong Lu","doi":"10.1016/j.breast.2024.103805","DOIUrl":"10.1016/j.breast.2024.103805","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the diagnosis performance of digital mammography (DM) and digital breast tomosynthesis (DBT), DM combined DBT with AI-based strategies for breast mass ≤ 2 cm.</div></div><div><h3>Materials and methods</h3><div>DM and DBT images in 483 patients including 512 breast masses were acquired from November 2018 to November 2019. Malignant and benign tumours were determined by biopsies using histological analysis and follow-up within 24 months. The radiomics and deep learning methods were employed to extract the breast mass features in images and finally for benign and malignant classification. The DM, DBT and DM combined DBT (DM + DBT) images were fed into radiomics and deep learning models to construct corresponding models, respectively. The area under the receiver operating characteristic curve (AUC) was employed to estimate model performance. An external dataset of 146 patients from March 2021 to December 2022 from another center was enrolled for external validation.</div></div><div><h3>Results</h3><div>In the internal testing dataset, compared with the DM model and the DBT model, the DM + DBT models based on radiomics and deep learning both showed statistically significant higher AUCs [0.810 (RA-DM), 0.823 (RA-DBT) and 0.869 (RA-DM + DBT), P ≤ 0.001; 0.867 (DL-DM), 0.871 (DL-DBT) and 0.908 (DL-DM + DBT), P = 0.001]. The deep learning models present superior to the radiomics models in the experiments with only DM (0.867 vs 0.810, P = 0.001), only DBT (0.871 vs 0.823, P = 0.001) and DM + DBT (0.908 vs 0.869, P = 0.003).</div></div><div><h3>Conclusions</h3><div>DBT has a clear additional value for diagnosing breast mass less than 2 cm compared with only DM. AI-based methods, especially deep learning, can help achieve excellent performance.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103805"},"PeriodicalIF":5.7,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S096097762400136X/pdfft?md5=23778896652ae9c47710fa8e71a02f2e&pid=1-s2.0-S096097762400136X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142312401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systematic review and meta-analysis of risk factors influencing patient-reported arm symptoms post-breast cancer treatment: Accounting for radiotherapy impact","authors":"Yuqin Liang ,&nbsp;Yuedan Zhou ,&nbsp;Ruud Houben ,&nbsp;Karolien Verhoeven ,&nbsp;Sofia Rivera ,&nbsp;Liesbeth J. Boersma","doi":"10.1016/j.breast.2024.103812","DOIUrl":"10.1016/j.breast.2024.103812","url":null,"abstract":"<div><h3>Objectives</h3><div>To systematically review risk factors for patient-reported arm symptoms (AS) in breast cancer (BC), considering radiotherapy (RT) impact, using the EORTC QLQ-BR23 questionnaire (BR23).</div></div><div><h3>Methods</h3><div>PubMed, Embase, Cochrane Library, MEDLINE, and Web of Science were searched using the keywords \"breast neoplasms\", \"radiotherapy\", and \"BR23\" up to March 5th, 2024. Inclusion criteria: both univariate and multivariate analyses. Exclusion criteria: pregnancy, recurrence, distant metastasis BC, reirradiation, or lack of RT. The risk of bias of included papers was assessed using the Critical Appraisal Skills Program (CASP) checklist. Descriptive and meta-analyses were conducted using risk ratio (RR) or standardized mean difference (SMD) with 95 % confidence intervals (CI) as effect measures. A random-effects model was applied if I² &gt; 50 %.</div></div><div><h3>Results</h3><div>Eighteen out of 734 studies were included, with sample sizes ranging from 172 to 2208. Commonly reported risk factors included axillary lymph node dissection (ALND), mastectomy, chemotherapy (CT), and RT (6, 5, 4, and 4 studies, respectively). In meta-analyses, ALND was a risk factor for arm pain (RR [95 % CI] = 1.75 [1.14; 2.71]), lymphedema (RR [95 % CI] = 5.41 [3.48; 8.39]), and overall AS (SMD [95 % CI] = 0.49 [0.14; 0.83]) compared to sentinel lymph node biopsy. RT was not a risk factor, but axillary RT significantly increased overall AS (SMD [95 % CI] = 0.55 [0.40; 0.70]) compared to no axillary RT.</div></div><div><h3>Conclusion</h3><div>ALND and mastectomy were the primary risk factors for patient-reported AS. Axillary RT was a significant risk factor, whereas general RT was not.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103812"},"PeriodicalIF":5.7,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001437/pdfft?md5=10ff023227409fb4ee60cd029f41a62c&pid=1-s2.0-S0960977624001437-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142315809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multimodal ultrasound assessment of mass and non-mass enhancements by MRI: Diagnostic accuracy in idiopathic granulomatous mastitis and breast cancer","authors":"Liang Yin ,&nbsp;Xi Wei ,&nbsp;Qing Zhang ,&nbsp;Lingling Xiang ,&nbsp;Yun Zhang ,&nbsp;Deqian Wang ,&nbsp;Peiqin Chen ,&nbsp;Xuan Cao ,&nbsp;Zakari Shaibu ,&nbsp;Rong Qin","doi":"10.1016/j.breast.2024.103797","DOIUrl":"10.1016/j.breast.2024.103797","url":null,"abstract":"<div><h3>Purpose</h3><div>Idiopathic granulomatous mastitis (IGM) poses diagnostic challenges due to its diverse clinical and radiological presentations, often mimicking malignancies. This study aimed to assess the diagnostic efficacy of multimodal ultrasound for mass and non-mass enhancements in Dynamic Contrast-Enhanced MRI (DCE-MRI) of IGM and breast cancer.</div></div><div><h3>Methods</h3><div>A retrospective analysis involved patients confirmed histopathologically with IGM and BC. All patients underwent conventional ultrasound (C-US), ultrasound elastography (UE), contrast-enhanced ultrasound (CEUS), and DCE-MRI examinations. Blinded experienced radiologists assessed imaging findings. Diagnostic accuracy, sensitivity, and specificity were calculated for mass and non-mass enhancements.</div></div><div><h3>Results</h3><div>For mass enhancements (ME), multimodal ultrasound demonstrated strong efficacy (AUC = 0.8651, 95 % CI: 0.7431 to 0.9871), exhibiting high sensitivity (83.3 %) and specificity (92.4 %) in differentiating IGM from breast cancer. However, for non-mass enhancements (NME), multimodal ultrasound showed limited accuracy (AUC = 0.6306) with lower sensitivity (65.6 %) and specificity (81.2 %) in distinguishing between IGM and breast cancer.</div></div><div><h3>Conclusion</h3><div>Multimodal ultrasound displayed good diagnostic efficacy for mass enhancements in DCE-MRI for IGM and breast cancer, while for non-mass enhancement patterns, DCE-MRI remains the most valuable radiological modality for comprehensively assessing this condition's complexities.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103797"},"PeriodicalIF":5.7,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142442917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of [18F]FDG PET/CT in patients with invasive breast carcinoma of no special type: Literature review and comparison between guidelines","authors":"David Groheux ,&nbsp;Sofia C. Vaz ,&nbsp;Philip Poortmans ,&nbsp;Ritse M. Mann ,&nbsp;Gary A. Ulaner ,&nbsp;Gary J.R. Cook ,&nbsp;Elif Hindié ,&nbsp;John Patrick Pilkington Woll ,&nbsp;Heather Jacene ,&nbsp;Isabel T. Rubio ,&nbsp;Marie-Jeanne Vrancken Peeters ,&nbsp;Elizabeth H. Dibble ,&nbsp;Lioe-Fee de Geus-Oei ,&nbsp;Stephanie L. Graff ,&nbsp;Fatima Cardoso","doi":"10.1016/j.breast.2024.103806","DOIUrl":"10.1016/j.breast.2024.103806","url":null,"abstract":"<div><h3>Purpose</h3><p>The recently released EANM/SNMMI guideline, endorsed by several important clinical and imaging societies in the field of breast cancer (BC) care (ACR, ESSO, ESTRO, EUSOBI/ESR, EUSOMA), emphasized the role of [¹⁸F]FDG PET/CT in management of patients with no special type (NST) BC. This review identifies and summarizes similarities, discrepancies and novelties of the EANM/SNMMI guideline compared to NCCN, ESMO and ABC recommendations.</p></div><div><h3>Methods</h3><p>The EANM/SNMMI guideline was based on a systematic literature search and the AGREE tool. The level of evidence was determined according to NICE criteria, and 85 % agreement or higher was reached regarding each statement. Comparisons with NCCN, ESMO and ABC guidelines were examined for specific clinical scenarios in patients with early stage through advanced and metastatic BC.</p></div><div><h3>Results</h3><p>Regarding initial staging of patients with NST BC, [¹⁸F]FDG PET/CT is the preferred modality in the EANM-SNMMI guideline, showing superiority as a single modality to a combination of contrast-enhanced CT of thorax-abdomen-pelvis plus bone scan in head-to-head comparisons and a randomized study. Its use is recommended in patients with clinical stage IIB or higher and may be useful in certain stage IIA cases of NST BC. In NCCN, ESMO, and ABC guidelines, [¹⁸F]FDG PET/CT is instead recommended as complementary to conventional imaging to solve inconclusive findings, although ESMO and ABC also suggest [¹⁸F]FDG PET/CT can replace conventional imaging for staging patients with high-risk and metastatic NST BC. During follow up, NCCN and ESMO only recommend diagnostic imaging if there is suspicion of recurrence. Similarly, EANM-SNMMI states that [¹⁸F]FDG PET/CT is useful to detect the site and extent of recurrence only when there is clinical or laboratory suspicion of recurrence, or when conventional imaging methods are equivocal. The EANM-SNMMI guideline is the first to emphasize a role of [¹⁸F]FDG PET/CT for assessing early metabolic response to primary systemic therapy, particularly for HER2+ BC and TNBC. In the metastatic setting, EANM-SNMMI state that [¹⁸F]FDG PET/CT may help evaluate bone metastases and determine early response to treatment, in agreement with guidelines from ESMO.</p></div><div><h3>Conclusions</h3><p>The recently released EANM/SNMMI guideline reinforces the role of [¹⁸F]FDG PET/CT in the management of patients with NST BC supported by extensive evidence of its utility in several clinical scenarios.</p></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103806"},"PeriodicalIF":5.7,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001371/pdfft?md5=594ebfbce36c5b0c62a7e5446683b6bc&pid=1-s2.0-S0960977624001371-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142274887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atypical ductal or lobular hyperplasia, lobular carcinoma in-situ, flat epithelial atypia, and future risk of developing breast cancer: Systematic review and meta-analysis","authors":"Jannah Baker ,&nbsp;Naomi Noguchi ,&nbsp;M Luke Marinovich ,&nbsp;Brian L. Sprague ,&nbsp;Elizabeth Salisbury ,&nbsp;Nehmat Houssami","doi":"10.1016/j.breast.2024.103807","DOIUrl":"10.1016/j.breast.2024.103807","url":null,"abstract":"<div><h3>Background</h3><p>Biopsy-proven breast lesions such as atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS) and flat epithelial atypia (FEA) increase subsequent risk of breast cancer (BC), but long-term risk has not been synthesized. A systematic review was conducted to quantify future risk of breast cancer accounting for time since diagnosis of these high-risk lesions.</p></div><div><h3>Methods</h3><p>A systematic search of literature from 2000 was performed to identify studies reporting BC as an outcome following core-needle or excision biopsy histology diagnosis of ADH, ALH, LCIS, lobular neoplasia (LN) or FEA. Meta-analyses were conducted to estimate cumulative BC incidence at five-yearly intervals following initial diagnosis for each histology type.</p></div><div><h3>Results</h3><p>Seventy studies reporting on 47,671 subjects met eligibility criteria. BC incidence at five years post-diagnosis with a high-risk lesion was estimated to be 9.3 % (95 % CI 6.9–12.5 %) for LCIS, 6.6 % (95 % CI 4.4–9.7 %) for ADH, 9.7 % (95 % CI 5.3–17.2 %) for ALH, 8.6 % (95 % CI 6.5–11.4 %) for LN, and 3.8 % (95 % CI 1.2–11.7 %) for FEA. At ten years post-diagnosis, BC incidence was estimated to be 11.8 % (95 % CI 9.0–15.3 %) for LCIS, 13.9 % (95 % CI 7.8–23.6 %) for ADH, 15.4 % (95 % CI 7.2–29.3 %) for ALH, 17.0 % (95 % CI 7.2–35.3 %) for LN and 7.2 % (95 % CI 2.2–21.2 %) for FEA.</p></div><div><h3>Conclusion</h3><p>Our findings demonstrate increased BC risk sustained over time since initial diagnosis of high-risk breast lesions, varying by lesion type, with relatively less evidence for FEA.</p></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103807"},"PeriodicalIF":5.7,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001383/pdfft?md5=90f4ed83118422b63c55aacd89e17b30&pid=1-s2.0-S0960977624001383-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142172863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of different exercise types on quality of life in patients with breast cancer: A network meta-analysis of randomized controlled trials","authors":"Liang Li,&nbsp;Yutong Wang,&nbsp;Mingzhou Cai,&nbsp;Tonggang Fan","doi":"10.1016/j.breast.2024.103798","DOIUrl":"10.1016/j.breast.2024.103798","url":null,"abstract":"<div><h3>Background</h3><p>Exercise is a rehabilitation strategy for patients with breast cancer; however, the optimal type of exercise remains uncertain. This study aimed to compare the effects of five exercise types on the quality of life of patients with breast cancer and provide a basis for their exercise rehabilitation.</p></div><div><h3>Methods</h3><p>As of May 2024, we searched four databases: Embase, PubMed, Web of Science, and Cochrane Library, and included randomized controlled trials that analyzed the effect of exercise on the quality of life of patients with breast cancer. A network meta-analysis was performed using a frequency-based framework.</p></div><div><h3>Results</h3><p>Forty-five papers involving 4092 participants were included. The five types of exercises included were all significant in the direct comparison with the control group, except yoga and mind–body exercises. Aerobic, resistance, and combination exercises were associated with quality of life. However, in indirect comparisons, only mind–body exercise versus resistance exercise had a significant effect. The effect of exercise on the quality of life(total health status) of patients with breast cancer was ranked based on surface under the cumulative ranking curve (SUCRA) values combined with effect sizes as follows: aerobic exercise (SUCRA = 84.1) &gt; combined exercise (SUCRA = 78.8) &gt; resistance exercise (SUCRA = 66.4) &gt; yoga (SUCRA = 39.3) &gt; mind-body exercise (SUCRA = 27.2) &gt; usual care (SUCRA = 4.1).</p></div><div><h3>Conclusions</h3><p>Exercise can rehabilitate the quality of life of patients with breast cancer, and aerobic exercise may be the best type of exercise to improve their quality of life(total health status).</p></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103798"},"PeriodicalIF":5.7,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001292/pdfft?md5=12013e3b0e68510d8c11bc049a75bd6e&pid=1-s2.0-S0960977624001292-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stereotactic body radiotherapy using CyberKnife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of dosimetric characteristics and preliminary clinical results","authors":"Ting-Na Wei ,&nbsp;Jia-Fu Lin ,&nbsp;Mei-Chun Cheng ,&nbsp;Hui-Ling Yeh","doi":"10.1016/j.breast.2024.103796","DOIUrl":"10.1016/j.breast.2024.103796","url":null,"abstract":"<div><h3>Introduction</h3><p>We compared the dosimetric characteristics of the target and organs at risk (OARs) as well as the preliminary clinical outcomes between two accelerated partial breast irradiation (APBI) techniques.</p></div><div><h3>Methods</h3><p>Forty-four patients diagnosed with left-sided early breast cancer who underwent APBI using either interstitial brachytherapy (IB) or stereotactic body radiation therapy (SBRT) with CyberKnife (CK) were retrospectively reviewed. The dosimetric parameters of the target and OARs were compared. Preliminary clinical outcomes, including tumor control and acute toxicity, were analyzed.</p></div><div><h3>Results</h3><p>Treatment plans with CK demonstrated a better cardiac dose-sparing effect. Radiation doses to the heart at V_150cGy for the CK and IB groups were 24.4 % and 60.4 %, respectively (<em>p</em> &lt; 0.001), while the mean heart doses for the CK and IB groups were 107.4 cGy and 204 cGy, respectively (<em>p</em> &lt; 0.001). The heart D_1c.c. and the ipsilateral lung received a lower dose in the IB group, without any significant differences. The median follow-up time in the CK and IB groups was 28.6 and 61.3 months, respectively. No patients died from either breast cancer or cardiac events during follow-up. A locoregional recurrence event at the neck occurred in one patient within the IB group.</p></div><div><h3>Conclusions</h3><p>APBI planned by CK was shown to have a better dose-sparing effect on the heart, as well as better conformity and homogeneity to the target. CK is a non-invasive treatment which showed minimal acute toxicity and promising tumor control.</p></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"78 ","pages":"Article 103796"},"PeriodicalIF":5.7,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0960977624001279/pdfft?md5=c187a162a0112bd2369b3e57ba9a8251&pid=1-s2.0-S0960977624001279-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}